Withdrawal: Makena
Apr. 2023Pharmacy Updates
On March 7, 2023, Covis Pharma announced that it is withdrawing Makena (hydroxyprogesterone caproate injection; also referred to as 17-OHPC) from the market. This drug is used to reduce the risk of preterm birth in women who are pregnant with one baby and have a history of spontaneous preterm birth. Read more about the Makena withdrawal.
Recent Announcements
CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care
Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.Sep. 2026Education/Webinars
Voluntary nationwide recall: Thyroid (Vitruvias – August 2026)
Vitruvias Therapeutics Inc. is recalling one lot, lot 504950, of Thyroid Tablets, USP 30 mg. Thyroid Tablet is used to treat hypothyroidism (underactive thyroid).Sep. 2026Pharmacy Updates
Voluntary nationwide recall: Dextrose (Baxter – August 2026)
Baxter International Inc. is recalling one lot (lot Y495066) of 70% Dextrose Injection. Dextrose is used to replenish calories and fluid in certain situations.Sep. 2026Pharmacy Updates